« Return to News | Study Conduct

UK firms go to Russia to conduct cheaper clinical trials

Tuesday, September 20, 2011 11:13 AM

Britain's fastest-growing bio-technology firms are flocking to Russia to run clinical trials more cheaply and quickly than they can in the West, according to This is MONEY.

The Kremlin is providing generous backing for Rusnano, a nanotechnology venture fund. It is also luring biotech firms in a bid to establish Russia as a leading center for pharmaceutical research and development.

It takes “half the time and one tenth of the cost” to run clinical trials in Russia, according to the boss of Xenetic Biosciences. The London-based firm is developing 12 drugs in Russia with Anglo-Russian collaboration and Rusnano funding.

Scott Maguire, chief executive of Xenetic, said, “Regulators do not take as much time to make a decision in Russia and the data you need to go into a trial is not as extensive as in Britain and the US.”

“More biotechs will consider taking this route. Where else are companies going to get the tens of millions of pounds required to run clinical trials?” said Maguire.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.